Geftiget 250mg Tablet

PRODUCT INTRODUCTION

Geftiget 250mg Tablet is a medication belonging to the class of tyrosine kinase inhibitors (TKIs). It contains Gefitinib as its active ingredient. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has certain mutations (specifically, mutations in the epidermal growth factor receptor or EGFR). Geftiget 250mg Tablet works by inhibiting the activity of EGFR, which plays a crucial role in the growth and spread of cancer cells. This medication is typically prescribed by oncologists or pulmonologists and is available in tablet form for oral administration.

 USES OF Geftiget 250mg Tablet

Geftiget 250mg Tablet is primarily used for the treatment of non-small cell lung cancer (NSCLC) in patients who have specific mutations in the epidermal growth factor receptor (EGFR). It is specifically indicated for patients with locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. This medication may also be used in other cases as determined by the prescribing healthcare provider.

 BENEFITS OF Geftiget 250mg Tablet

The main benefit of Geftiget 250mg Tablet is its ability to effectively target and inhibit EGFR, a protein that plays a crucial role in the growth and spread of cancer cells, particularly in NSCLC patients with specific mutations. By blocking the activity of EGFR, Geftiget helps slow down or halt the progression of the disease, thereby improving the patient’s prognosis and quality of life. Additionally, it may also help alleviate symptoms associated with NSCLC, such as difficulty breathing, coughing, and chest pain.

SIDE EFFECTS OF Geftiget 250mg Tablet

Like all medications, Geftiget 250mg Tablet may cause side effects in some individuals. Common side effects may include diarrhea, skin rash, acne, dry skin, nausea, vomiting, loss of appetite, and fatigue. Some patients may also experience more serious side effects such as interstitial lung disease (ILD), liver problems, eye disorders (including changes in vision), and gastrointestinal perforation. It is important for patients to report any unusual symptoms or side effects to their healthcare provider promptly. Additionally, regular monitoring and follow-up appointments are essential to monitor for potential side effects and adjust treatment as needed.

References